Basilar Artery Occlusion Chinese Endovascular Registry in Patients With Large-Core Infarct (NCT07345702) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Basilar Artery Occlusion Chinese Endovascular Registry in Patients With Large-Core Infarct
China518 participantsStarted 2026-01-31
Plain-language summary
This multicenter retrospective registry study evaluates the safety and effectiveness of endovascular therapy versus medical therapy for acute large-core basilar artery occlusion. It also investigates clinical, imaging, and laboratory factors associated with functional outcomes and mortality. Patients are grouped according to the treatment received in routine clinical practice.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Age ≥18 years, men or women.
. Occlusion (TIMI 0-1) of the basilar artery or intracranial segments of both vertebral arteries (V4) as evidenced by CTA/MRA/DSA.
. Time from symptom onset (or last known well) to treatment (endovascular therapy or medical therapy) ≤7 days.
. Patients with large core infarction in the posterior circulation, defined as a posterior circulation Acute Stroke Prognosis Early CT score (pc-ASPECTS) score of 0-5 on CT angiography source images or MR with diffusion-weighted imaging or non-contrast CT.
Exclusion criteria
. Subjects with occlusions in both anterior and posterior circulation.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Proportion of Patients Achieving mRS 0-3 at 90 Days
. CT or MR evidence of hemorrhage (the presence of microbleeds on MRI is allowed).
. Missing key clinical information (e.g., unavailable baseline NIHSS, unclear symptom onset/last known well time, or missing major treatment information including whether EVT was performed).
. Baseline NIHSS score \<6.
. Woman of childbearing potential who is known to be pregnant or lactating or who has a positive pregnancy test on admission.
. Missing follow-up outcomes at 90 days.
. Any other condition judged by investigators to substantially affect analysis or interpretation.